Here's Why You Should Buy Align Technology (ALGN) Stock Now

Zacks03-26

Align Technologies ALGN is well-poised to grow in the coming quarters, backed by thesignificant opportunity for Invisalign's expansion into the vast, untapped global malocclusion market. The growing ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2422191886?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/H9DYdttPy00EKBHhcxtlCA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9f2a2e04a053cda7a8c096e532e43d28","is_english":true,"pubTime":"2024-03-26 20:44","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2422191886","market":"us","top_or_hot":-1,"title":"Here's Why You Should Buy Align Technology (ALGN) Stock Now","media":"Zacks","content":"<div>\n<p>Align Technologies ALGN is well-poised to grow in the coming quarters, backed by thesignificant opportunity for Invisalign's expansion into the vast, untapped global malocclusion market. The growing ...</p>\n\n<a href=\"https://finance.yahoo.com/news/heres-why-buy-align-technology-124400840.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's Why You Should Buy Align Technology (ALGN) Stock Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's Why You Should Buy Align Technology (ALGN) Stock Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-03-26 20:44 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/heres-why-buy-align-technology-124400840.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Align Technologies ALGN is well-poised to grow in the coming quarters, backed by thesignificant opportunity for Invisalign's expansion into the vast, untapped global malocclusion market. The growing ...</p>\n\n<a href=\"https://finance.yahoo.com/news/heres-why-buy-align-technology-124400840.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1267930227.SGD","symbol_name":"TEMPLETON GLOBAL BALANCED \"AS\" (SGD) ACC A","start_time":0,"source_url":"https://finance.yahoo.com/news/heres-why-buy-align-technology-124400840.html","article_id":"2422191886","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/H9DYdttPy00EKBHhcxtlCA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9f2a2e04a053cda7a8c096e532e43d28"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2422191886","pubTimestamp":1711457040,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Align Technologies ALGN is well-poised to grow in the coming quarters, backed by thesignificant opportunity for Invisalign's expansion into the vast, untapped global malocclusion market. The growing demand for iTero intraoral scanners and exocad CAD/CAM software buoys optimism. Further, the company’s slew of strategic alliances looks impressive.However, substantial dependence on the Invisalign system and currency fluctuations remain concerning for ALGN.In the past year, this Zacks Rank #3  stock has increased 4.4% compared with the 15.8% rise of the industryand 31.8% growth of the S&P 500 composite.The renowned medical device company has a market capitalization of $23.99 billion. ALGN projects an estimated earnings growth rate of 9.1% for 2024 compared with 7.4% of the industry. ALGN’s earnings surpassed estimates in three of the trailing four quarters and missed in one, the average surprise being 5.8%.","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1267930227.SGD":"TEMPLETON GLOBAL BALANCED \"AS\" (SGD) ACC A","SYK":"史赛克","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","ALGN":"艾利科技","LU0052756011.USD":"TEMPLETON GLOBAL BALANCED \"A\" (USD) INC","LU2404859667.USD":"FUNDSMITH EQUITY FUND \"R\" (USD) ACC","LU0310799852.SGD":"FTIF - Templeton Global Equity Income A MDIS SGD","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","LU0128525689.USD":"TEMPLETON GLOBAL BALANCED \"A\"(USD) ACC","LU0211327993.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (USD) ACC","GB00B4LPDJ14.GBP":"FUNDSMITH EQUITY \"R\" (GBP) ACC","LU0889566641.SGD":"FTSF - Templeton Shariah Global Equity A Acc SGD","LU0528227936.USD":"富达环球人口趋势基金A-ACC","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","BK4175":"保健护理产品经销商","LU0690374615.EUR":"FUNDSMITH EQUITY \"R\" (EUR) ACC","BK4534":"瑞士信贷持仓","BK4585":"ETF&股票定投概念","CAH":"卡地纳健康","LU1267930813.SGD":"FRANKLIN TEMPLETON SHARIAH GLOBAL EQUITY \"AS\" (SGD) ACC","LU2404859741.USD":"FUNDSMITH EQUITY FUND \"R\" (USD) INC","LU0310800965.SGD":"FTIF - Templeton Global Balanced A Acc SGD","BK4566":"资本集团","BK4196":"保健护理服务","LU0690374961.EUR":"FUNDSMITH EQUITY \"R\" (EUR) INC","BK4082":"医疗保健设备","BK4559":"巴菲特持仓","LU1267930490.SGD":"TEMPLETON GLOBAL EQUITY INCOME \"AS\" (SGD) INC A","GB00B4QBRK32.GBP":"FUNDSMITH EQUITY \"R\" (GBP) INC","BK4588":"碎股","BK4198":"医疗保健用品","LU2023250504.SGD":"Allianz Thematica Cl AMg DIS H2-SGD","LU0792757196.USD":"TEMPLETON SHARIAH GLOBAL EQUITY FUND \"A\" (USD) ACC","BK4504":"桥水持仓","LU1791710582.SGD":"Fidelity Global Demographics A-ACC-SGD (SGD/USD hedged)","LU1917777945.USD":"安联专题基金Cl AT Acc","LU1791710400.SGD":"Fidelity Global Demographics A-ACC-SGD","LU2023250843.SGD":"Allianz Thematica Cl AT Acc H2-SGD","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","LU0006061336.USD":"Blackrock US Small and MidCap Opportunities A2 USD","LU0211328371.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (MDIS) (USD)   INC","DVA":"达维塔保健","LU0882574055.USD":"富达全球健康医疗A ACC"},"translate_title":"以下是你现在应该购买Align Technology（ALGN）股票的原因","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SYK":1,"ALGN":1,"DVA":1,"CAH":1},"content_text":"Align Technologies ALGN is well-poised to grow in the coming quarters, backed by thesignificant opportunity for Invisalign's expansion into the vast, untapped global malocclusion market. The growing demand for iTero intraoral scanners and exocad CAD/CAM software buoys optimism. Further, the company’s slew of strategic alliances looks impressive. However, substantial dependence on the Invisalign system and currency fluctuations remain concerning for ALGN.\nIn the past year, this Zacks Rank #3 (Hold) stock has increased 4.4% compared with the 15.8% rise of the industry and 31.8% growth of the S&P 500 composite.\nThe renowned medical device company has a market capitalization of $23.99 billion. ALGN projects an estimated earnings growth rate of 9.1% for 2024 compared with 7.4% of the industry. ALGN’s earnings surpassed estimates in three of the trailing four quarters and missed in one, the average surprise being 5.8%.\nLet’s delve deeper.\nUpsides\nInvisalign’s Untapped Potential: Align Technology is strategically capturing the growing malocclusion market, one of the most prevalent clinical dental conditions in the world. The company’s May 2023 data indicates that approximately 500 million people globally have malocclusion. However, most of them do not seek orthodontic treatment, mainly due to the negative perceptions of metal braces, affordability of treatment and accessibility to doctors in certain markets and geographies.\nImage Source: Zacks Investment Research\nAnnually, only 21 million people elect treatment by orthodontists, which means that a large portion of the patient base is unattended. ALGN noted that 90% of this patient base could be treated with Invisalign Clear Aligner, presenting a significant growth opportunity to increase its share in the existing global market of orthodontic case starts, especially among teens, and expand the market for digital orthodontics, especially among adults. By the end of 2023, the company had treated 17 million patients with Invisalign, including 4.7 million teens.\niTero in Focus: Align Technology’s iTero intraoral scanners and exocad CAD/CAM software are gaining prominence in the global dental market as the preferred scanning technology for digital dental scans and the dental restorative solution of choice for dental labs, respectively.  Beginning patient care with the early usage of iTero intraoral scanners and combining the results with digital workflows help visualize and evaluate various treatment options with detailed imagery and CAD/CAM solutions.\nIn the fourth quarter of 2023, ALGN introduced the iTero Lumina inter-oral scanner with a smaller wand and unparalleled data capture capabilities for scanning by clinical members. The scanner is presently available with orthodontic workflows and will be available in the second half of 2024 restorative workflows. Per the company, the use of iTero scanners for Invisalign case submissions continues to grow and remains a positive catalyst for Invisalign utilization.\nStrategic Alliances: Align Technology has well-established relationships with many DSOs in the United States and is continuously exploring collaboration to drive the adoption of digital dentistry. In 2023, the company focused on reaching young adults, teens and their parents in the Americas through influencer and creator-centric campaigns by partnering with leading smile squad creators, including Marshall Martin, Rally Shaw and Jeremy Lin.\nALGN also teamed up with Athletes Over Time, a high school sports social media platform that showcases the benefits of Invisalign treatment. In the EMEA region, the company partnered with new influencers to reach consumers across social media platforms, including TikTok and Meta. In Germany, Align Technology launched new testimonial campaigns, highlighting the stories of 70 young adults and teens who share why they chose Invisalign treatment and how it impacted their lives.\nDownsides\nCurrency Headwinds: During the fourth quarter of 2023, the unfavorable effect of foreign exchange reduced revenues and margins significantly for Align Technology. Clear aligner revenues witnessed an unfavorable foreign exchange impact of approximately $12.8 million or approximately 1.3% sequentially. Systems and services revenues were unfavorably impacted by approximately $2.1 million or approximately 1.2% sequentially.\nOverdependence on the Invisalign Technology System: The bulk of Align Technology's net revenues largely depend on the sale of its Invisalign Technology System, primarily Invisalign Technology Full and Invisalign Technology Teen. Therefore, continued and widespread market acceptance by orthodontists, GPs and consumers is critical to the company’s future success. Management is concerned that a shift in consumers’ preference toward a more competitive product can hamper the company’s operating results.\nEstimate Trend\nThe Zacks Consensus Estimate for Align Technologies’ 2024 earnings per share (EPS) has decreased to $9.39 from $9.46 in the past 30 days.\nThe Zacks Consensus Estimate for the company’s 2024 revenues is pegged at 4.04 billion. This suggests a 4.6% rise from the year-ago reported number.\nKey Picks\nSome better-ranked stocks in the broader medical space are Cardinal Health CAH, Stryker SYK and DaVita DVA.\nCardinal Health has a long-term estimated earnings growth rate of 14.2% compared with the industry’s 11.6%. CAH’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 15.6%. Its shares have increased 60% compared with the industry’s 17.4% rise in the past year.\nCAH carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.\nStryker, carrying a Zacks Rank #2 at present, has an earnings yield of 3.36% compared to the industry’s 0.02%. Shares of the company have increased 26.2% compared with the industry’s 7.5% rise over the past year.\nSYK’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 5.2%. In the last reported quarter, it delivered an average earnings surprise of 5.81%.\nDaVita, sporting a Zacks Rank #1 at present, has an estimated long-term earnings growth rate of 12.1% compared with the industry’s 11.9%. Shares of DVA have rallied 74.7% compared with the industry’s 22% rise over the past year.\nDVA’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 35.6%. In the last reported quarter, it delivered an average earnings surprise of 22.2%.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nStryker Corporation (SYK) : Free Stock Analysis Report\nDaVita Inc. (DVA) : Free Stock Analysis Report\nAlign Technology, Inc. (ALGN) : Free Stock Analysis Report\nCardinal Health, Inc. (CAH) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2422191886"}